Gilead Sciences, Inc. $GILD Shares Sold by DekaBank Deutsche Girozentrale

Key Points

• DekaBank Deutsche Girozentrale reduced its stake in Gilead Sciences by 0.8%, currently holding approximately 0.16% of the company, valued at $226.3 million.
• Gilead Sciences reported a quarterly revenue of $7.08 billion and earnings per share (EPS) of $2.01, exceeding analyst expectations.
• Analysts have upgraded their ratings on Gilead Sciences, with Citigroup increasing its price objective from $125.00 to $135.00 and others also notably raising their target prices.

DekaBank Deutsche Girozentrale decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,040,494 shares of the biopharmaceutical company's stock after selling 17,085 shares during the quarter. DekaBank Deutsche Girozentrale owned approximately 0.16% of Gilead Sciences worth $226,287,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences in the first quarter valued at about $25,000. Activest Wealth Management increased its holdings in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 227 shares during the last quarter. Harbor Asset Planning Inc. bought a new stake in Gilead Sciences in the second quarter valued at about $27,000. Goodman Advisory Group LLC bought a new stake in Gilead Sciences in the first quarter valued at about $29,000. Finally, Colonial Trust Advisors increased its holdings in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 213 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on GILD shares. Citigroup boosted their price objective on Gilead Sciences from $125.00 to $135.00 and gave the company a "buy" rating in a report on Wednesday, October 8th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a report on Friday, July 25th. The Goldman Sachs Group upped their target price on Gilead Sciences from $105.00 to $108.00 and gave the company a "neutral" rating in a report on Friday. UBS Group upped their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Finally, Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price for the company in a report on Tuesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $121.14.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $123.11 on Tuesday. Gilead Sciences, Inc. has a 12-month low of $85.60 and a 12-month high of $124.11. The firm has a market capitalization of $152.76 billion, a price-to-earnings ratio of 24.52, a price-to-earnings-growth ratio of 0.84 and a beta of 0.34. The business has a 50 day simple moving average of $115.27 and a 200 day simple moving average of $110.62. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same period in the prior year, the company posted $2.01 EPS. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's dividend payout ratio is 62.95%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer directly owned 157,055 shares of the company's stock, valued at $18,545,054.40. This represents a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares of the company's stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,500 shares of company stock valued at $8,281,540 in the last three months. 0.27% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.